(Q31955396)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11181291%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

review article

1 reference

title

Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11181291%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

1 reference

1 reference

1 reference

Helicobacter pylori infectious disease

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11181291%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

J María Pajares

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11181291%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11181291%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11181291%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11181291%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11181291%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

111-116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11181291%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Susceptibility of Helicobacter pylori to metronidazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

How long for the routine Helicobacter pylori antimicrobial susceptibility testing? The usefulness of the string test to obtain Helicobacter for culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Antibiotic resistance in Helicobacter pylori: implications for therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Role of metronidazole resistance in therapy of Helicobacter pylori infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Validation of a modified Kirby-Bauer disk diffusion method for metronidazole susceptibility testing of Helicobacter pylori.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Antimicrobial resistance testing of Helicobacter pylori: a comparison of Etest and disk diffusion methods.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Microbiological and serological diagnostic tests for Helicobacter pylori: an overview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

[Do we use reasonably macrolides in primary care?].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Non-endoscopic method to obtain Helicobacter pylori for culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Clinical relevance of resistant strains of Helicobacter pylori: a review of current data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Ranitidine bismuth citrate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2801%2971738-1

10.1016/S0025-7753(01)71738-1

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11181291%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference